Journal issue overview 2/2020 Athero Review

71

Michal Vrablík

72

Michal Vrablík

76

Therapy with drugs containing the active ingredient LOMITAPIDE in patients with homozygous form of familial hypercholesterolemia: a statement of the committee of the Czech Society for Atherosclerosis

Vladimír Bláha, Michal Vrablík, Vladimír Soška, Jan Piťha, Renata Cífková, Tomáš Freiberger, David Karásek, Pavel Kraml, Hana Rosolová, Tomáš Štulc, Zuzana Urbanová Za Výbor Čsat

83

How media affect fat choice

Jiří Brát

88

Genetic testing for early prediction of cardiovascular diseases: genome-wide association studies and polygenic score

Jaroslav A. Hubáček

93

Very low LDL cholesterol in acute coronary syndrome

Jan Piťha

99

Cardiovascular risk in patients with familial hypercholesterolemia. Do we rate it correctly?

Ubomíra Fábryová

107

Psychosocial cardiovascular risk factors

Jan Bruthans

113

Combined hypolipidemic therapy: case report

Marcel Nesva, Patrik Christian Cmorej, David Peřan, Jaroslav Pekara

117

LipitenCliDec Study – the profile of patients with uncontrolled arterial hypertension and/or dyslipidemia in primary care in the Czech Republic: the 2nd phase results

Martin Šatný, Eva Tůmová, Michal Vrablík, Jana Mašková, Jiří Laštůvka

124

New findings about alirocumab therapy from the common conference of the American College of Cardiology and the World Congress of Cardiology 2020

Ivan Tkáč

127

The timing for CV risk intervention as a critical success factor

Zuzana Zafarová, Michal Vrablík

131

Rešerše zajímavých článků ze zahraniční literatury

Eva Tůmová

133

Interaktivní webinář: 1. díl – Kardiovaskulární prevence a diabetes

Kristýna Čillíková

Athero Review - Issue 2/2020

Editorial

Personal News

Guidelines

Clinical Studies

Announcements

Athero Review